Trial reportDrug design, development and therapy2026
Anterior Quadratus Lumborum Block with Liposomal Bupivacaine versus Ropivacaine for Postoperative Recovery in Laparoscopic Colorectal Surgery: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical utility of liposomal bupivacaine (LB) in fascial plane blocks remains controversial, with many trials focusing on early postoperative outcomes. We investigated whether LB in quadratus lumborum block (QLB) provides an extended recovery benefit following laparoscopic colorectal surgery. Methods: In this randomized, double-blind, controlled, superiority trial, 120 patients undergoing laparoscopic colorectal surgery between May 12, 2025, and December 25, 2025, were allocated to receive ultrasound-guided QLB-3 with either 1.3% LB (266 mg) or 0.33% ropivacaine (132 mg). The primary outcome was the Quality of Recovery-15 (QoR-15) score at 48 hours postoperatively (POD 2). Secondary outcomes included QoR-15 at 24 hours (POD 1), opioid consumption, and safety profiles. Results: Analyzed via a linear mixed-effects model, the LB group demonstrated a significantly improved postoperative recovery trajectory compared to the ropivacaine group (P Conclusion: Liposomal bupivacaine in quadratus lumborum blocks provided a statistically significant improvement in QoR 15 scores at 48 hours and an opioid sparing effect. However, the observed 4.38 point difference did not meet the prespecified minimal clinically important difference. This suggests that while the intervention provides a statistical benefit, its clinical impact may be modest within the context of an established ERAS pathway. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2500097657).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.